Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04134559
Other study ID # 19-338
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date November 1, 2020
Est. completion date January 1, 2025

Study information

Verified date September 2023
Source Dana-Farber Cancer Institute
Contact DFCI Clinical Trials Hotline
Phone 877-DF-TRIAL
Email allison_oneill@dfci.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This research study is studying an immunotherapy drug (pembrolizumab or KEYTRUDA) as a possible treatment for pediatric hepatocellular carcinoma or hepatocellular neoplasm not otherwise specified (HCN NOS).


Description:

Patients who fulfill eligibility criteria will be entered into the trial to receive pembrolizumab or KEYTRUDA This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. In the case of this trial, the investigators are studying whether pembrolizumab can treat pediatric hepatocellular carcinoma. The FDA (the U.S. Food and Drug Administration) has not approved pembrolizumab for your specific disease but it has been approved for other uses in adults. Checkpoint inhibitors are in early-phase study in pediatric patients across diagnoses. In this research study, the investigators plan to investigate whether pediatric patients with hepatocellular carcinoma experience stable disease or response to pembrolizumab. In addition, the investigators would like to explore different biological factors of the tumor and immune system that might help us predict whether pediatric patients with HCC may benefit from treatment with pembrolizumab.


Recruitment information / eligibility

Status Recruiting
Enrollment 18
Est. completion date January 1, 2025
Est. primary completion date January 1, 2025
Accepts healthy volunteers No
Gender All
Age group 0 Years to 30 Years
Eligibility Inclusion Criteria: - Age: Patients must be <30 years of age at the time of study enrollment. - Diagnosis: Patients must have relapsed/refractory, histologically confirmed HCC to be eligible for enrollment. Patients with hepatocellular neoplasm not otherwise specified (HCN NOS) will also be eligible. - Disease Status: Participants must have measurable disease by RECIST criteria, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) measured at =20 mm with conventional technique or =10 mm with spiral CT scan, MRI, or calipers by clinical exam. See Section 10 for the evaluation of measurable disease. - Performance Level: Karnofsky performance status = 60% for patients = 16 years of age or Lansky = 60% for patients < 16 years of age. - Prior Therapy: Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy. - Patients must not have received standard or targeted treatment regimens within 14 days of initiation of treatment with pembrolizumab. - Patients must not have received prior radiotherapy within 7 days of initiation of treatment with pembrolizumab. Patients who have experienced radiation-induced adverse events must recover to a grade 1 prior to enrollment. - Organ Function Requirements: Participants must have normal organ and marrow function as defined below: - Adequate Bone Marrow Function defined as: - Peripheral absolute neutrophil count (ANC) = 750/µL - Platelet count = 75,000/µL (can be transfused) - Adequate Liver Function defined as: - Total bilirubin < 1.5 x institutional upper limit of normal (ULN) - AST(SGOT) = 2.5 x ULN - ALT(SGPT) = 2.5 x ULN - If liver function studies are more elevated than the thresholds above, and if if this elevation is felt secondary to tumor, patients may still be eligible for enrollment after discussion with the study PI. - Adequate Renal and Metabolic Function defined as: - A serum creatinine based on age/gender as follows: - Age Maximum Serum Creatinine (mg/dL) Male Female - 1 to <2 years 0.6 0.6 - 2 to <6 years 0.8 0.8 - 6 to <10 years 1.0 1.0 - 10 to <13 years 1.2 1.2 - 13 to <16 years 1.5 1.4 - >16 years 1.7 1.4 - OR - Creatinine clearance =60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal. - Amylase = 1.5 x ULN - Lipase = 1.5 x ULN - If liver function studies are more elevated than the thresholds above, and if this elevation is felt secondary to tumor, patients may still be eligible for enrollment after discussion with the study PI. -- Adequate Thyroid Function defined as: --- TSH =1.5 ULN. Patients can be receiving thyroid supplementation. - Confirmation of Insurance Pre-authorization approval for Pembrolizumab. - Patients, their parent, and/or legally authorized representative must be able to understand and be willing to sign a written informed consent document. Assent for participants < 18 years will follow institutional guidelines. The protocol will require approval by each institution's Institutional Review Board. - The effects of pembrolizumab on the developing human fetus are unknown. For this reason, patients of child-bearing and child-fathering potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 4 months after completion of pembrolizumab administration. Should a female become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Males treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of pembrolizumab administration. - Women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy test within 24 hours of each treatment. - A tumor sample must be available for submission to the central laboratory (Dana-Farber Cancer Institute, see Section 9). If surgery was performed at the time of recurrence, this sample, in addition to a diagnostic sample should be submitted. If no re-operation was performed, archived tissue from diagnosis or the most recent procedure should be submitted (see section 9 for further details regarding tissue specifications). Exclusion Criteria: - Participants who are receiving any other investigational agents are not eligible. - Participants who have received checkpoint inhibitors (PD-1, PD-L1, and CTLA-4 inhibitors) are not eligible. - Participants who have received antibody-based therapies are not eligible if they are within 3 half-lives of receipt of the last antibody dose. - Participants who are receiving chronic steroids are not eligible.Chronic steroids are defined as either > or = 2mg/kg/day of body weight or > or = 20mg/day of prednisone or equivalent for persons who weigh > or = 10kg administered for > or = 14 consecutive days. - Participants who are receiving anti-inflammatory or immunosuppressive medications are not eligible. - Participants with known autoimmune disease, with the exceptions of childhood asthma or atopic dermatitis, are not eligible. - Patients with a history of a positive test for human immunodeficiency virus or acquired immunodeficiency syndrome are not eligible. - Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab are not eligible. History of severe allergy to monoclonal antibody therapies (i.e. anaphylaxis) are likewise an exclusion. - Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, or psychiatric illness/social situations that would limit compliance with study requirements are not eligible. - Patients with prior solid organ transplantation are not eligible.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pembrolizumab
Pembrolizumab will be administered every 3 weeks, at predetermined dose with 21 consecutive days defined as a treatment cycle.

Locations

Country Name City State
United States Children's Hospital Boston Boston Massachusetts
United States Dana Farber Cancer Institute Boston Massachusetts
United States Cincinnati Children's Medical Center Cincinnati Ohio
United States Baylor College of Medicine Houston Texas
United States University of California San Francisco San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
Allison O'Neill, MD

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Immune-related best overall response (irBOR) irRECIST criteria 63 Days
Secondary Progression-free survival (PFS) irRECIST criteria enrollment to progression (defined by irRECIST criteria) or death (whichever event occurs first), or to date of last contact up to 100 months
Secondary Expression levels of infiltrating immune cells and markers of checkpoint inhibition on pre-treatment specimens Expression levels of infiltrating immune cells and markers of checkpoint inhibition, as assessed by immunohistochemistry on pre-treatment specimens, quantified using a semi-quantitative scoring system based on percent of cells showing positive staining. 2 Years
Secondary Percent change immune cell phenotype, cytokines, and circulating tumor DNA summarized using descriptive statistics. 2 Years
Secondary Number of Participants with DLT organ affected or laboratory determination, severity (by NCI CTCAE v5.0), and attribution. 2 Years
Secondary DNA sequencing of specimens Descriptive analysis of gene mutation patterns correlating with disease response to checkpoint inhibition 2 Years
See also
  Status Clinical Trial Phase
Completed NCT03213314 - HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies N/A
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Completed NCT03756597 - PAN-study: Pan-Cancer Early Detection Study (PAN)
Recruiting NCT05160740 - Indocyanine Green Molecular Fluorescence Imaging Technique Using in Diagnosis and Treatment of Primary Liver Cancer N/A
Completed NCT01906021 - Study of New Software Used During Ablations N/A
Terminated NCT04589884 - Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
Recruiting NCT05953337 - Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) N/A
Enrolling by invitation NCT04466124 - Prospective Cohort Study of Liver Cancer Patients Treated With Proton Beam Therapy
Not yet recruiting NCT04053231 - Hepatocarcinoma Recurrence on the Liver Study - Part2
Active, not recruiting NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Phase 1
Completed NCT03059238 - Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure Phase 3
Recruiting NCT02632188 - Radical Surgery Followed by Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen for the Treatment of Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT01388101 - Real-time Diagnosis of Serum LECT 2 in Patient With Liver Cancer Using Electronic Antibody Sensor (e- Ab Sensor) N/A
Terminated NCT00903396 - Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Phase 2
Completed NCT01042041 - Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer Phase 1
Completed NCT00980239 - HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver Phase 1
Completed NCT00790569 - Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking N/A
Terminated NCT00896467 - Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy N/A
Completed NCT00543777 - Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease Phase 1/Phase 2